newsfilter
← Latest News
Earnings Call Transcripts·

Q3 2026 IRIDEX Earnings Conference Call - IRIDEX CORP

  • Explicit Guidance:

    • Full-year 2026 revenue guidance updated to $46–$48 million, excluding revenue from the Middle East.
    • Full-year 2026 adjusted operating expenses (non-GAAP) expected to range between $19–$19.5 million.
    • No specific 2027 revenue, earnings, or margin guidance provided; however, management expects 2027 to be the first full year realizing combined benefits of cost savings and margin initiatives, resulting in "operating profits."
    • Q4 2026 revenue anticipated in the range of $11.5–$13.5 million (implied from FY guidance and Q1–Q3 actuals), with a potential to be adjusted EBITDA positive at the higher end of this range.
  • Business-Segment Outlook:

    • Glaucoma (Cyclo-G6): U.S. market remains a growth driver driven by Medicare LCD tailwinds, MedScout commercial focus, and sustained higher average selling prices (ASP); probe volume held steady in the U.S. (6,900 units) while system placements increased (8 units vs. 7 prior year). International probe volume expected to recover sequentially in Q4, though year-over-year growth is not anticipated. Global G6 probe volume expected to grow as international distributor inventory burn completes.
    • Retina (Pascal): U.S. Pascal revenue is on a strong upward trajectory (up ~50% YoY) and expected to continue gaining share; international growth constrained by regulatory delays (MDR certification) and competitive pricing. Pascal MDR approval anticipated in the first half of 2027, which is expected to unlock solid demand in Europe. Japan Pascal shipments deferred in Q3 (approx. $300k) expected to realize in Q4.
    • Product Rationalization: A comprehensive strategic review is underway to streamline product lines, reduce portfolio complexity, and exit non-profitable geographies and product lines to focus on higher-margin revenue streams. This may involve accepting lower top-line revenue in specific regions to achieve stronger margins and lower cost-to-serve.
  • Market and Competitive Outlook:

    • Pricing Power: Pricing discipline maintained in the U.S. with G6 probe ASPs increased in 2025 and held through 2026; U.S. market share for Pascal growing due to clinical data and physician education.
    • Competitive Pressure: International Retina markets face aggressive pricing pressure from larger competitors; Glaucoma systems in Europe face competition from the Artibay platform (note: transcript mentions "Artbox" and "Artibay," interpreted as Artibay competitor).
    • Market Dynamics: International distributor behavior continues to create volatility; inventory accumulation in early 2026 led to order deferrals in Q3, with a trend toward order replenishment in Q4 as safety stock converts to revenue.
  • Macro / Industry Outlook:

    • Regulatory Environment: Regulatory delays for new Pascal MDR certification in Europe (Germany, Austria) and India are the primary near-term headwinds for Retina; approvals expected in H1 2027.
    • Geopolitical & Economic Factors: Economic weakness in China and Japan continues to dampen order activity; the ongoing conflict in the Middle East (specifically Saudi Arabia) continues to weigh on regional activity, leading to its exclusion from guidance. Rising energy costs from the Iran war are noted as impacting business in Asia and Europe.
    • Currency/Supply: Structural supply chain shifts are ongoing to mitigate regulatory address changes; inventory management remains a key focus to stabilize cash flow.
  • Strategic Initiatives:

    • Manufacturing Relocation: Completed October 2026; moved operations from Mountain View to San Jose, delivering $600,000 in annualized rent savings (approx. $300k allocated to cost of sales) and operational efficiency gains as the site integrates.
    • Contract Manufacturing: Transition of major products to third-party contract manufacturers is on track to complete in 2026, with gross margin expansion expected to materialize fully in 2027.
    • Cost Reduction: Ongoing evaluation of additional operating expense reductions for 2027, including potential outsourcing of functions overseas and further administrative streamlining.
    • Cash Flow: Safety stock built during the manufacturing transition is converting to revenue; cash flow break-even is the stated priority for the remainder of 2026.
  • Risks and Headwinds to Outlook:

    • Regulatory Delays: Continued delays in Pascal MDR approval in Europe and India could push revenue recognition and volume growth into 2027 or beyond.
    • Competitive Pricing: Aggressive pricing in international retina markets and competitive pressure in glaucoma could limit volume or pricing power.
    • Macroeconomic Volatility: Economic stagnation in China and Japan, and geopolitical instability in the Middle East, pose risks to international revenue recovery.
    • Inventory Dynamics: The pace of distributor inventory conversion and the effectiveness of safety stock utilization could deviate from expectations.
    • Revenue Exclusions: Exclusion of Middle East revenue from guidance creates a lower baseline for total reported revenue.
  • Management Tone on the Future:

    • Management expresses cautious optimism regarding 2027, framing it as the year of "structural progress" and "sustainable profitability."
    • Tone is defensive regarding 2026, acknowledging Q3 results fell short due to specific headwinds, but emphasizes that actions taken (relocation, cost cutting) are designed to make 2027 "a more profitable year."
    • Confidence is high in the long-term value proposition of micropulse therapy and U.S. franchise strength, while admitting international markets require "decisive steps" to address volatility.
    • Strategic shift is clearly toward quality over quantity, explicitly stating they will not enter or remain in markets that do not generate profit.
  • Miscellaneous:

    • Cash Position: Ended Q3 2026 with $3.7 million in cash and cash equivalents; net cash used in operating activities was $1.0 million driven by inventory buildup.
    • Financial Metrics: Q3 2026 gross margin improved to 42.4% (38.7% pro forma excluding one-time write-offs), up 370 bps YoY. Q3 Adjusted Operating Expenses were $5.5 million.
    • Timeline: Q4 2026 is expected to be the strongest quarter for probe and system placements, acting as a transition period before the 2027 profitability inflection.
Company
IRIDEX CORP
Keywords
IRIDEX CORP